Scarica l'app Stockscreener
53.84
0.34%
0.18
Dopo l'orario di chiusura:
53.89
0.05
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
Will Akero Therapeutics Inc. (0K4) stock remain on Wall Street radarRate Cut & Weekly Sector Rotation Insights - Trung tâm Dự báo KTTV quốc gia
Is Akero Therapeutics Inc. stock a buy before product launchesFed Meeting & Smart Money Movement Alerts - newser.com
Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger - MSN
How Akero Therapeutics Inc. stock compares to industry benchmarksTake Profit & Safe Capital Growth Stock Tips - Trung tâm Dự báo KTTV quốc gia
Will earnings trigger a reversal in Akero Therapeutics Inc.Market Risk Report & Reliable Trade Execution Plans - newser.com
Custom watchlist performance reports with Akero Therapeutics Inc.Market Trend Summary & Daily Oversold Stock Bounce Ideas - newser.com
Advanced analytics toolkit walkthrough for Akero Therapeutics Inc.Weekly Trading Summary & Community Verified Trade Signals - newser.com
Is Akero Therapeutics Inc a good long term investmentHigh Dividend Yield Stocks & Access Free Risk Analysis Before You Invest - earlytimes.in
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (NasdaqAKRO), CoreCard Corporation (NYSECCRD), PB Bankshares, Inc. (Nasdaq - GlobeNewswire Inc.
Can a trend reversal in Akero Therapeutics Inc. lead to recoveryEarnings Recap Summary & High Conviction Buy Zone Alerts - newser.com
Will Akero Therapeutics Inc. stock gain from lower inflationBear Alert & Low Drawdown Momentum Trade Ideas - newser.com
Understanding Momentum Shifts in (AKRO) - news.stocktradersdaily.com
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead - MarketBeat
Will Akero Therapeutics Inc. stock reach Wall Street targetsJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com
Is Akero Therapeutics Inc. stock bottoming outEarnings Overview Summary & Free High Return Stock Watch Alerts - newser.com
Akero Therapeutics Inc. (AKRO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Akero Therapeutics CEO Cheng sells $1.62m in shares By Investing.com - Investing.com Australia
Biotech Fund Beating 92% of Peers Sees More M&A Deals to Come - Bloomberg.com
Akero Therapeutics CEO Cheng sells $1.62m in shares - Investing.com
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio - Zenopa
Akero Therapeutics, Inc. $AKRO Stake Trimmed by Aberdeen Group plc - MarketBeat
Is Akero Therapeutics Inc. forming a bottoming baseJuly 2025 WrapUp & Long-Term Safe Return Strategies - newser.com
StockWatch: Novo Nordisk Raises MASH Bet with Up-to-$5.2B Akero Acquisition - Genetic Engineering and Biotechnology News
Novo Nordisk to Acquire Akero Therapeutics for $4.7B - contractpharma.com
TD Cowen Downgrades Akero Therapeutics to Hold From Buy, Adjusts Price Target to $58 From $76 - MarketScreener
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring a 20% Upside Potential in Biotech - DirectorsTalk Interviews
Novo Nordisk to acquire Akero Therapeutics for up to USD 5.2 billion - Medical Dialogues
Real time breakdown of Akero Therapeutics Inc. stock performanceMarket Activity Summary & Daily Momentum Trading Reports - newser.com
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion - Indian Pharma Post
The week in pharma: action, reaction and insight – week to October 10 - The Pharma Letter
Akero Therapeutics (NASDAQ:AKRO) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Lowered to Hold Rating by Wolfe Research - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Cut to "Neutral" at HC Wainwright - MarketBeat
Lifesci Capital Downgrades Akero Therapeutics (NASDAQ:AKRO) to Hold - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Insider Sells $576,000.00 in Stock - MarketBeat
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc.AKRO - Business Wire
Akero Therapeutics (NASDAQ:AKRO) Shares Gap UpShould You Buy? - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An - GlobeNewswire
Akero Therapeutics Acquired by Novo Nordisk for $5.2B - The Globe and Mail
Akero Therapeutics (NASDAQ:AKRO) Cut to Hold at Jefferies Financial Group - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
Quantitative breakdown of Akero Therapeutics Inc. recent moveWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - newser.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Yahoo Finance
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
How to recover losses in Akero Therapeutics Inc. stockJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - newser.com
Novo Nordisk: New CEO Executing on Focused Strategy With Akero Acquisition - Morningstar Canada
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance? - Zacks Investment Research
Wolfe Research Downgrades Akero Therapeutics (AKRO) to Peer Perf - GuruFocus
Wolfe Research Downgrades Akero Therapeutics to Peer Perform From Outperform - MarketScreener
HC Wainwright Downgrades Akero Therapeutics to Neutral From Buy, $72 Price Target - MarketScreener
Novo makes bold $5.2bn bet on MASH treatment with Akero buy - BioXconomy
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):